Recombinant Human THBS1, N-His

Description of Recombinant Human THBS1, N-His

Introduction

Recombinant Human THBS1, N-His is a protein that has been genetically engineered to mimic the structure and function of the human thrombospondin-1 (THBS1) protein. It is commonly referred to as a drug target due to its potential therapeutic applications in various diseases. In this article, we will explore the structure, activity, and potential applications of Recombinant Human THBS1, N-His.

Structure of Recombinant Human THBS1, N-His

Recombinant Human THBS1, N-His is a 117 kDa protein composed of 1170 amino acids. It contains a unique N-terminal His tag, which allows for easy purification and detection of the protein. The His tag is followed by the full-length sequence of the THBS1 protein, including all five thrombospondin type-1 repeats (TSRs) and the C-terminal domain. The TSRs are known to be involved in cell adhesion and protein-protein interactions, while the C-terminal domain is responsible for the anti-angiogenic activity of THBS1.

Activity of this protein

Recombinant Human THBS1, N-His has been shown to exhibit similar activity to the native THBS1 protein. It is known to play a crucial role in regulating cell adhesion, migration, and proliferation. It does so by binding to various cell surface receptors, including integrins, CD36, and syndecans. These interactions can activate signaling pathways that control cell behavior, such as the PI3K/Akt and MAPK pathways.

Additionally, Recombinant Human THBS1, N-His has potent anti-angiogenic activity. It can inhibit the formation of new blood vessels by binding to and sequestering vascular endothelial growth factor (VEGF), a key protein involved in angiogenesis. This activity makes it a potential therapeutic agent for diseases characterized by excessive angiogenesis, such as cancer and diabetic retinopathy.

Applications of Recombinant Human THBS1, N-His

Recombinant Human THBS1, N-His has been studied extensively for its potential therapeutic applications. One of its most promising uses is in cancer treatment. THBS1 is known to have anti-tumor activity by inhibiting angiogenesis and promoting tumor cell death. Recombinant Human THBS1, N-His has been shown to have similar effects, making it a potential candidate for cancer therapy.

In addition to cancer, Recombinant Human THBS1, N-His has shown potential in treating other diseases, such as diabetic retinopathy, a condition characterized by abnormal blood vessel growth in the retina. By inhibiting angiogenesis, Recombinant Human THBS1, N-His can potentially prevent or slow down the progression of this disease.

Furthermore, Recombinant Human THBS1, N-His has also been studied for its potential role in tissue regeneration and wound healing. THBS1 is known to promote cell migration and tissue repair, and Recombinant Human THBS1, N-His has been shown to have similar effects in preclinical studies.

Conclusion

In summary, Recombinant Human THBS1, N-His is a genetically engineered protein that mimics the structure and activity of the native THBS1 protein. It has been shown to have similar activity to THBS1 and has potential applications in various diseases, including cancer, diabetic retinopathy, and tissue regeneration. Its unique structure and activity make it a promising drug target for future research and development.